Loading…
Loading…
PXMD does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PXMD and 80,000+ other tickers.
See exactly how PXMD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PXMD and 80,000+ other tickers.
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and…
Profitability This table compares PaxMedica and ProMetic Life Sciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% ProMetic Life Sciences -894.02% -3,350.55% -67.76% Risk and Volatility PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and PaxMedica (NASDAQ: PXMD - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 30.5% of Leap Therapeutics
BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism. Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been approved, since it was first used in humans over 100 years ago.
TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.
Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home.